DIA In Focus Newsletter – Pharmacovigilance
Collaborate on DIA Research: Data in Clinical Development
We are launching a research initiative to help further the adoption and implementation of artificial intelligence in adverse event reporting and safety monitoring. This research brings industry leaders, regulators, academic institutions, and clinical networks together to generate innovative approaches and results.
Learn more about this research?here.
Fill out?this form?to?receive more information.
Highlight Session from the?Global Pharmacovigilance and Risk Management Strategies Conference
Research Integrity in the Quest for Therapies for Alzheimer’s Disease
This session provides a historic perspective of experimental anti-amyloid therapies for Alzheimer’s disease and centers on recent concerns about the amyloid cascade hypothesis. The presented scenario highlights the persistent risk of research misconduct and the responsibility of co-authors, funders, publishers, and regulatory bodies for maintaining data integrity.
DIA’s Pharmacovigilance History, Legacy, and Portfolio
?DIA was founded in 1964 by a group of 30 pharmaceutical professionals, medical writers, and academicians who, in the midst of the thalidomide crisis in Europe, saw the need to facilitate communications and foster cooperative efforts among professionals who were engaged in drug development, medical communications, and health information. Since its inception, DIA has developed an education, training, and publication portfolio designed to advance the science of pharmacovigilance and enhance patient safety and care in the use of medicines around the world.
Download?this overview?of DIA’s pharmacovigilance history, legacy, and portfolio.
领英推荐
The?Global Annual Meeting Clinical Safety and Pharmacovigilance Track
?Get an expert overview of the global regulatory environment in the field of clinical safety and pharmacovigilance for medical products. The Clinical Safety and PV track focuses on pragmatic approaches to protecting patient safety and incorporating the patient voice into the complex and evolving pharmacovigilance ecosystem. Topic areas include:
From?Therapeutic Innovation & Regulatory Science
This first systematic review evaluates PV performance in developing countries and provides an in-depth understanding of factors affecting PV system performance.
Amid a turbulent political, economic, and health context, Lebanon has been able to develop one of the most active and rapidly evolving PV systems in the Middle East. Implementation of PV systems in resource-limited countries is a real challenge. How could Lebanon establish a national PV system during the pandemic and?without guaranteed funding?
Join DIA’s Clinical Safety & Pharmacovigilance (CSP) Community
We provide a collaborative environment and forum for professionals across the CSP landscape to share, evaluate, and disseminate information on processes, standards, and technologies for the management of safety and pharmacovigilance data. We foster best practices, new ideas, and discussions around the changing regulatory environment to enhance the practice of monitoring the safety of drugs, biologics, and devices.